We are live on ! Find out more
EWTX icon

Edgewise Therapeutics

192 hedge funds and large institutions have $2.32B invested in Edgewise Therapeutics in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 68 increasing their positions, 63 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more call options, than puts

Call options by funds: $61.6M | Put options by funds: $32.7M

11% more funds holding in top 10

Funds holding in top 10: 910 (+1)

6.09% more ownership

Funds ownership: 104.55%110.64% (+6.1%)

8% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 63

4% less funds holding

Funds holding: 200192 (-8)

12% less capital invested

Capital invested by funds: $2.64B → $2.32B (-$321M)

16% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 38

Holders
192
Holders Change
-8
Holders Change %
-4%
% of All Funds
2.57%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.13%
New
32
Increased
68
Reduced
63
Closed
38
Calls
$61.6M
Puts
$32.7M
Net Calls
+$28.9M
Net Calls Change
+$15.4M
Name Holding Trade Value Shares
Change
Change in
Stake
PCH
51
Polar Capital Holdings
United Kingdom
$5.5M +$6.56M +250,000 New
UBS Group
52
UBS Group
Switzerland
$5.37M +$3.98M +151,830 +165%
CS
53
Candriam SCA
Luxembourg
$4.97M -$739K -28,169 -11%
KCM
54
Kennedy Capital Management
Missouri
$4.94M -$313K -11,942 -5%
GIM
55
Granahan Investment Management
Massachusetts
$4.79M -$2.16M -82,346 -27%
Bank of New York Mellon
56
Bank of New York Mellon
New York
$4.64M -$8.42K -321 -0.2%
CM
57
Caption Management
Oklahoma
$4.5M +$5.36M +204,500 New
N
58
Nuveen
North Carolina
$4.46M -$5.94M -226,278 -53%
Amundi
59
Amundi
France
$4.19M -$867K -33,054 -10%
Fidelity Investments
60
Fidelity Investments
Massachusetts
$4.09M -$1.63M -62,013 -25%
DCM
61
DAFNA Capital Management
California
$4.03M -$105K -4,000 -2%
MAP
62
Moody Aldrich Partners
Massachusetts
$4.01M -$153K -5,837 -3%
SC
63
Stempoint Capital
New York
$3.97M +$1.25M +47,549 +36%
Susquehanna International Group
64
Susquehanna International Group
Pennsylvania
$3.89M +$3.8M +144,953 +457%
D.E. Shaw & Co
65
D.E. Shaw & Co
New York
$3.09M -$14.3M -545,823 -80%
Jennison Associates
66
Jennison Associates
New York
$2.83M +$3.38M +128,746 New
Balyasny Asset Management
67
Balyasny Asset Management
Illinois
$2.66M +$2.56M +97,546 +418%
Wellington Management Group
68
Wellington Management Group
Massachusetts
$2.49M -$2.35M -89,590 -44%
RhumbLine Advisers
69
RhumbLine Advisers
Massachusetts
$2.39M +$169K +6,440 +6%
Barclays
70
Barclays
United Kingdom
$2.39M -$658K -25,095 -19%
EAM
71
EFG Asset Management
Oregon
$2.3M +$1.65M +63,048 +153%
ABG
72
Ally Bridge Group
New York
$2.26M +$511K +19,474 +23%
Neuberger Berman Group
73
Neuberger Berman Group
New York
$2.25M +$2.68M +102,181 New
TC
74
TwinBeech Capital
New York
$2.22M +$2.65M +100,826 New
Citadel Advisors
75
Citadel Advisors
Florida
$2.14M -$9.76M -372,173 -79%

EWTX Hedge Fund Activity: Q1 2025 in Review

192 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q1 2025, worth a combined $2.32B — down 12% from $2.64B a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of EWTX and 32 opened new positions — a net loss of 6 holders — while 63 trimmed existing stakes and 68 added.

The largest buyer was Perceptive Advisors, adding an estimated $101M. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $33.9M sold.

  • 192 institutional investors held Edgewise Therapeutics (EWTX) as of Q1 2025, down from 200 in Q4 2024.
  • Funds reported $2.32B of Edgewise Therapeutics stock for Q1 2025, down 12% quarter-over-quarter.
  • 32 funds opened new Edgewise Therapeutics positions in Q1 2025 and 38 closed out, a net change of -6 holders.
  • The largest Edgewise Therapeutics buyer in Q1 2025 was Perceptive Advisors, an estimated $101M added.
  • The largest Edgewise Therapeutics seller in Q1 2025 was Frazier Life Sciences Management, an estimated $33.9M sold.

Based on aggregated 13F filings for Q1 2025.